PCSK9 antagonists
AssigneesIrm LLC, Novartis AG
InventorsSarah Rue, Steve B. Cohen, Jun Li, David Yowe
Life of this patent
Estimating the term…
Abstract
The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
Claims20
An antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the antibody comprises a heavy chain V-segment and a light chain V-segment, each of which comprises a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2), and a complementarity determining region 3 (CDR3);
- wherein:
- i) the CDR1 of the heavy chain V-segment comprises SEQ ID NO:7;
- ii) the CDR2 of the heavy chain V-segment comprises SEQ ID NO:10;
- iii) the heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13;
- iv) the CDR1 of the light chain V-segment comprises SEQ ID NO:21;
- v) the CDR2 of the light chain V-segment comprises SEQ ID NO:24;
- and
- vi) the light chain CDR3 comprises SEQ ID NO:26.
An antibody that specifically binds PCSK9, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region each comprise the following three complementarity determining regions (CDRs):
- CDR1, CDR2 and CDR3;
- wherein:
- i) the CDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8;
- ii) the CDR2 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:11;
- iii) the CDR3 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:14;
- iv) the CDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:22;
- v) the CDR2 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:25;
- vi) the CDR3 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:26.
An antibody that specifically binds PCSK9, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region each comprise the following three complementarity determining regions (CDRs):
- CDR1, CDR2 and CDR3, wherein:
- i) the CDR1 of the heavy chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:7;
- ii) the CDR2 of the heavy chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:10;
- iii) the CDR3 of the heavy chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13;
- iv) the CDR1 of the light chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NO:20 and SEQ ID NO:21;
- v) the CDR2 of the light chain variable region comprises the amino acid sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:24;
- vi) the CDR3 of the light chain variable region comprises the amino acid sequence of SEQ ID NO:26.
Dependencies are inferred from the claim text.